OncoC4 Reports the First Patient Dosing in P-I Study of ONC-841 for Solid Tumors
Shots:
- OncoC4 has dosed the first patient in FIH P-I (ONC-841-002) study of ONC-841 for treating solid tumors
- The P-I trial assesses the safety, efficacy & PK of ONC-841 (7 dose levels, IV, Q4W) alone for treating advanced and or metastatic solid tumors across the US, with initial data anticipated in 2025
- ONC-841 is a humanized anti-SIGLEC10 mAb, that works by blocking SIGLEC10's interaction with CD24, enabling immune cells like NK cells, macrophages & T cells to attack tumors. It has shown enhanced cancer cell phagocytosis, tumor-infiltrating immune cell function & antibody-dependent cell-mediated cytotoxicity (ADCC) in preclinical studies
Ref: OncoC4 | Image: OncoC4
Related News:- BioNTech and OncoC4 Initiate Pivotal P-III Trial of Gotistobart (BNT316/ONC-392) in Patients with Metastatic Non Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
